8-K Announcements
6Material company update
Apr 10, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Mar 6, 2026·SEC
Solid Biosciences Inc.(SLDB)Earnings, Financials & Key Ratios
SLDB•NASDAQ
Price updated Jun 19, 2026
AboutSolid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$178M-39.5%
- Net Income-$174M-39.8%
- EPS (Diluted)-1.99+35.0%
- ROE-109.9%-16.2%
SLDB Key Insights
Solid Biosciences Inc. (SLDB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 14.6% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SLDB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLDB Price & Volume
Solid Biosciences Inc. (SLDB) stock price & volume — 10-year historical chart
Loading chart...
SLDB Growth Metrics
Solid Biosciences Inc. (SLDB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-37.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM30.11%
Return on Capital
10 Years-77.11%
5 Years-65.27%
3 Years-79.34%
Last Year-100.26%
SLDB Recent Earnings
Solid Biosciences Inc. (SLDB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.52-30.0%
$0.40
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.50+2.0%
$0.51
Rev
—
—
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.48-14.3%
$0.42
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.42+17.6%
$0.51
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.52vs $0.40-30.0% | — |
| Q2 2026 | Mar 19, 2026 | $0.50vs $0.51+2.0% | — |
| Q4 2025 | Nov 3, 2025 | $0.48vs $0.42-14.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.42vs $0.51+17.6% | — |
Based on last 12 quarters of dataView full earnings history →
SLDB Peer Comparison
Solid Biosciences Inc. (SLDB) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare SLDB vs Peers
Solid Biosciences Inc. (SLDB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLDB Income Statement
Solid Biosciences Inc. (SLDB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 13.62M | 8.09M | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | -40.57% | -100% | - | - | - |
Cost of Goods Sold | 0 | 1.57M | 2.82M | 3.92M | 0 | 0 | 2.58M | 2.46M | 1.64M | 781K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -448K▲ 0% | -1.57M▼ 249.6% | -2.82M▼ 80.3% | -3.92M▼ 38.9% | 13.62M▲ 447.3% | 8.09M▼ 40.6% | -2.58M▼ 131.9% | -2.46M▲ 4.9% | -1.64M▲ 33.4% | -781K▲ 0% |
Gross Margin % | - | - | - | - | 100% | 100% | - | - | - | - |
Gross Profit Growth % | -700% | -249.55% | -80.33% | -38.88% | 447.27% | -40.57% | -131.89% | 4.88% | 33.36% | - |
Operating Expenses | 54.86M | 75.69M | 119.32M | 82.54M | 85.87M | 114.55M | 101.73M | 127.27M | 177.57M | 195.68M |
OpEx % of Revenue | - | - | - | - | 630.5% | 1415.2% | - | - | - | - |
Selling, General & Admin | 14.95M | 17.72M | 24.58M | 21.58M | 27.14M | 28.95M | 27.75M | 33.3M | 38.88M | 40.91M |
SG&A % of Revenue | - | - | - | - | 199.23% | 357.65% | - | - | - | - |
Research & Development | 39.91M | 57.97M | 94.74M | 64.88M | 58.74M | 78.42M | 76.56M | 96.43M | 140.32M | 155.55M |
R&D % of Revenue | - | - | - | - | 431.27% | 968.87% | - | - | - | - |
Other Operating Expenses | 0 | 270K | 0 | -3.92M | 0 | 7.18M | -2.58M | -2.46M | -1.64M | -781K |
Operating Income | -54.86M▲ 0% | -75.69M▼ 38.0% | -119.32M▼ 57.6% | -86.46M▲ 27.5% | -72.25M▲ 16.4% | -106.45M▼ 47.3% | -104.31M▲ 2.0% | -129.73M▼ 24.4% | -179.21M▼ 38.1% | -196.46M▲ 0% |
Operating Margin % | - | - | - | - | -530.5% | -1315.2% | - | - | - | - |
Operating Income Growth % | -114.49% | -37.97% | -57.65% | 27.54% | 16.43% | -47.33% | 2.01% | -24.36% | -38.14% | - |
EBITDA | -54.41M | -74.12M | -116.49M | -82.54M | -69.29M | -104.04M | -101.73M | -127.27M | -177.57M | -194.84M |
EBITDA Margin % | - | - | - | - | -508.74% | -1285.45% | - | - | - | - |
EBITDA Growth % | -113.2% | -36.23% | -57.17% | 29.15% | 16.05% | -50.16% | 2.22% | -25.1% | -39.52% | -38.79% |
D&A (Non-Cash Add-back) | 448K | 1.57M | 2.82M | 3.92M | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M | 1.62M |
EBIT | -54.86M | -74.8M | -119.32M | -88.29M | -72.25M | -99.27M | -96.02M | -124.36M | -179.21M | -191.91M |
Net Interest Income | 0 | 0 | 1.58M | 115K | 64K | 2.62M | 7.14M | 9.13M | 9.9M | 9.6M |
Interest Income | 219K | 619K | 1.58M | 115K | 64K | 2.62M | 7.14M | 9.47M | 9.9M | 9.66M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 340K | 0 | 60K |
Other Income/Expense | 1.68M | 889K | 2.1M | -1.83M | 66K | 20.47M | 8.3M | 5.03M | 4.88M | 4.68M |
Pretax Income | -53.18M▲ 0% | -74.8M▼ 40.7% | -117.22M▼ 56.7% | -88.29M▲ 24.7% | -72.19M▲ 18.2% | -85.98M▼ 19.1% | -96.02M▼ 11.7% | -124.7M▼ 29.9% | -174.32M▼ 39.8% | -191.78M▲ 0% |
Pretax Margin % | - | - | - | - | -530.01% | -1062.28% | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -52.12M▲ 0% | -74.8M▼ 43.5% | -117.22M▼ 56.7% | -88.29M▲ 24.7% | -72.19M▲ 18.2% | -85.98M▼ 19.1% | -96.02M▼ 11.7% | -124.7M▼ 29.9% | -174.32M▼ 39.8% | -191.78M▲ 0% |
Net Margin % | - | - | - | - | -530.01% | -1062.28% | - | - | - | - |
Net Income Growth % | -141.97% | -43.52% | -56.72% | 24.68% | 18.24% | -19.11% | -11.67% | -29.87% | -39.8% | -37.3% |
Net Income (Continuing) | -53.18M | -74.8M | -117.22M | -88.29M | -72.19M | -85.98M | -96.02M | -124.7M | -174.32M | -191.78M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -24.26▲ 0% | -33.73▼ 39.0% | -43.05▼ 27.6% | -25.50▲ 40.8% | -10.14▲ 60.2% | -10.10▲ 0.4% | -4.83▲ 52.2% | -3.06▲ 36.6% | -1.99▲ 35.0% | -1.75▲ 0% |
EPS Growth % | -44.4% | -39.04% | -27.63% | 40.77% | 60.24% | 0.39% | 52.18% | 36.65% | 34.97% | 30.11% |
EPS (Basic) | -24.26 | -33.73 | -43.05 | -25.50 | -10.14 | -10.10 | -4.83 | -3.06 | -1.99 | - |
Diluted Shares Outstanding | 2.15M | 2.22M | 2.69M | 3.46M | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M | 109.81M |
Basic Shares Outstanding | 2.15M | 2.22M | 2.69M | 3.46M | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M | 109.81M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SLDB Balance Sheet
Solid Biosciences Inc. (SLDB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 70.66M | 128.64M | 86.3M | 158.9M | 222.61M | 219.64M | 129.73M | 157.3M | 205.46M | 396.79M |
Cash & Short-Term Investments | 69.09M | 122.46M | 83.52M | 154.74M | 207.78M | 213.72M | 123.64M | 148.92M | 187.85M | 381.32M |
Cash Only | 52.08M | 86.37M | 76.04M | 154.74M | 119.14M | 155.38M | 74.02M | 80.23M | 59.9M | 297.74M |
Short-Term Investments | 17.01M | 36.1M | 7.48M | 0 | 88.64M | 58.34M | 49.63M | 68.69M | 127.95M | 83.58M |
Accounts Receivable | 0 | 0 | 0 | 0 | 110K | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | 2.95 | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 613K | 1.81M | 1.49M | 1.48M | 8.71M | 3M | 2.11M | 1.65M | 17.61M | 2.98M |
Total Non-Current Assets | 5.54M | 10.96M | 17.17M | 12.27M | 9.77M | 40.61M | 35.2M | 31.36M | 27.08M | 26.1M |
Property, Plant & Equipment | 2.43M | 10.42M | 16.63M | 11.73M | 7.6M | 38.61M | 33.16M | 29.04M | 26.09M | 25.21M |
Fixed Asset Turnover | - | - | - | - | 1.79x | 0.21x | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.48M |
Other Non-Current Assets | 3.11M | 536K | 536K | 536K | 2.16M | 2.01M | 2.04M | 2.32M | 991K | 183K |
Total Assets | 76.19M▲ 0% | 139.6M▲ 83.2% | 103.47M▼ 25.9% | 171.17M▲ 65.4% | 232.38M▲ 35.8% | 260.25M▲ 12.0% | 164.94M▼ 36.6% | 188.66M▲ 14.4% | 232.54M▲ 23.3% | 422.89M▲ 0% |
Asset Turnover | - | - | - | - | 0.06x | 0.03x | - | - | - | 0.00x |
Asset Growth % | 87.5% | 83.21% | -25.88% | 65.43% | 35.76% | 11.99% | -36.62% | 14.38% | 23.26% | 109.01% |
Total Current Liabilities | 11.27M | 12.48M | 18.28M | 24.48M | 23.6M | 22.51M | 14.52M | 30.26M | 33.47M | 30.28M |
Accounts Payable | 5.07M | 3.69M | 7.12M | 3.27M | 4.46M | 3.24M | 2.03M | 4.24M | 3.22M | 5.56M |
Days Payables Outstanding | - | 860.29 | 920.77 | 304.69 | - | - | 287.36 | 629.94 | 719.29 | 2.56K |
Short-Term Debt | 0 | 173K | 0 | 0 | 0 | 0 | 0 | 0 | 2.1M | 2.19M |
Deferred Revenue (Current) | 233K | 8.23M | 0 | 10.36M | 8.08M | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.17M | 4.91M | 3.63M | 3.83M | 3.12M | 8.38M | 5.95M | 9.37M | 28.14M | 18.15M |
Current Ratio | 6.27x | 10.31x | 4.72x | 6.49x | 9.43x | 9.76x | 8.94x | 5.20x | 6.14x | 13.10x |
Quick Ratio | 6.27x | 10.31x | 4.72x | 6.49x | 9.43x | 9.76x | 8.94x | 5.20x | 6.14x | 13.10x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 124.18M | 1.93M | 5.15M | 14.6M | 568K | 26.08M | 23.94M | 21.16M | 19.06M | 18.48M |
Long-Term Debt | 0 | 859K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 859K | 5.15M | 2.94M | 568K | 25.98M | 23.94M | 21.16M | 19.06M | 77.31M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 215K | 0 | 1.3M | 0 | 96K | 0 | 0 | 0 | 0 |
Total Liabilities | 135.45M | 14.41M | 23.42M | 39.08M | 24.17M | 48.59M | 38.46M | 51.42M | 52.53M | 48.76M |
Total Debt | 0 | 1.03M | 7.07M | 5.15M | 2.06M | 28.55M | 26.27M | 24.18M | 21.16M | 20.67M |
Net Debt | -52.08M | -85.33M | -68.97M | -149.59M | -117.07M | -126.84M | -47.75M | -56.06M | -38.74M | -277.07M |
Debt / Equity | - | 0.01x | 0.09x | 0.04x | 0.01x | 0.13x | 0.21x | 0.18x | 0.12x | 0.06x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.42x |
Interest Coverage | - | - | - | - | - | - | - | -365.76x | - | -3198.45x |
Total Equity | -59.26M▲ 0% | 125.18M▲ 311.3% | 80.05M▼ 36.1% | 132.09M▲ 65.0% | 208.21M▲ 57.6% | 211.67M▲ 1.7% | 126.48M▼ 40.2% | 137.25M▲ 8.5% | 180.01M▲ 31.2% | 374.13M▲ 0% |
Equity Growth % | -56.41% | 311.25% | -36.06% | 65.01% | 57.63% | 1.66% | -40.24% | 8.51% | 31.16% | 122.36% |
Book Value per Share | -27.57 | 56.44 | 29.80 | 38.15 | 29.25 | 24.87 | 6.36 | 3.36 | 2.06 | 3.41 |
Total Shareholders' Equity | -59.26M | 125.18M | 80.05M | 132.09M | 208.21M | 211.67M | 126.48M | 137.25M | 180.01M | 374.13M |
Common Stock | 65.01M | 35K | 48K | 87K | 7K | 20K | 20K | 40K | 79K | 98K |
Retained Earnings | -124.26M | -199.06M | -316.28M | -404.57M | -476.76M | -562.74M | -658.75M | -783.45M | -957.77M | -1.01B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -13K | -5K | 1K | 0 | -45K | -68K | 15K | 47K | 52K | -13K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLDB Cash Flow Statement
Solid Biosciences Inc. (SLDB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -43.22M | -70.2M | -92.71M | -56.6M | -77.76M | -97.98M | -94.18M | -100.01M | -156.29M | -171.67M |
Operating CF Margin % | - | - | - | - | -570.95% | -1210.49% | - | - | - | - |
Operating CF Growth % | -114.83% | -62.4% | -32.08% | 38.95% | -37.39% | -25.99% | 3.88% | -6.19% | -56.27% | -244.4% |
Net Income | -53.18M | -74.8M | -117.22M | -88.29M | -72.19M | -85.98M | -96.02M | -124.7M | -174.32M | -191.78M |
Depreciation & Amortization | 448K | 1.57M | 2.82M | 3.92M | 2.96M | 2.41M | 2.58M | 2.46M | -1.87M | -2.18M |
Stock-Based Compensation | 5.33M | 5.96M | 14.21M | 11.63M | 13.37M | 7.54M | 7.63M | 10.52M | 16.91M | 18.73M |
Deferred Taxes | 206K | 0 | 0 | 0 | 1.21M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -459K | -86K | -277K | -20K | -81K | -18.25M | -2.03M | 8.86M | 9.82M | 9.88M |
Working Capital Changes | 4.43M | -2.83M | 7.75M | 16.16M | -23.04M | -3.69M | -6.34M | 2.85M | -6.82M | -6.31M |
Change in Receivables | 0 | 0 | 0 | 0 | -110K | 110K | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | -11.5M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.58M | -1.61M | 3.78M | -3.43M | 1.21M | -5.25M | -764K | 2.21M | -1.09M | 767K |
Cash from Investing | 10.55M | -26.76M | 24.52M | 6.6M | -91.09M | 59.16M | 9.69M | -16.09M | -58.45M | 13.77M |
Capital Expenditures | -2.28M | -7.78M | -4.39M | -899K | -1.28M | -3.02M | -1.51M | -654K | -1.15M | -1.19M |
CapEx % of Revenue | - | - | - | - | 9.41% | 37.25% | - | - | - | - |
Acquisitions | 0 | 0 | -24.52M | -7.5M | 89.81M | 31.52M | 0 | 5K | 85K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 100K | -18.99M | 24.52M | 7.5M | -89.81M | 600K | 0 | 0 | 0 | 85K |
Cash from Financing | 77.08M | 131.51M | 57.88M | 128.7M | 134.99M | 74.83M | 3.12M | 122.44M | 194.45M | 243.75M |
Debt Issued (Net) | 0 | -13K | 0 | 0 | 0 | 2.08M | 0 | -473K | -723K | -588K |
Equity Issued (Net) | 79.5M | 133.69M | 49.33M | 128.7M | 134.88M | 72.55M | 2.97M | 122.12M | 194.74M | 243.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.11M | 0 | 0 |
Other Financing | -2.42M | -2.17M | 8.55M | 0 | 107K | 203K | 148K | 794K | 425K | 425K |
Net Change in Cash | 44.4M▲ 0% | 34.55M▼ 22.2% | -10.32M▼ 129.9% | 78.7M▲ 862.4% | -33.87M▼ 143.0% | 36.01M▲ 206.3% | -81.37M▼ 326.0% | 6.34M▲ 107.8% | -20.3M▼ 420.2% | 85.84M▲ 0% |
Free Cash Flow | -45.5M▲ 0% | -77.97M▼ 71.4% | -97.1M▼ 24.5% | -57.5M▲ 40.8% | -79.05M▼ 37.5% | -100.99M▼ 27.8% | -95.69M▲ 5.2% | -100.67M▼ 5.2% | -157.44M▼ 56.4% | -172.86M▲ 0% |
FCF Margin % | - | - | - | - | -580.36% | -1247.74% | - | - | - | - |
FCF Growth % | -121.82% | -71.37% | -24.53% | 40.79% | -37.47% | -27.77% | 5.24% | -5.19% | -56.4% | -61.1% |
FCF per Share | -21.17 | -35.15 | -36.15 | -16.61 | -11.10 | -11.86 | -4.81 | -2.47 | -1.80 | -1.57 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.94x | 0.79x | 0.64x | 1.08x | 1.14x | 0.98x | 0.80x | 0.90x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLDB Key Ratios
Solid Biosciences Inc. (SLDB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -226.91% | -114.24% | -83.24% | -42.43% | -40.96% | -56.79% | -94.57% | -109.9% | -74.45% |
Return on Invested Capital (ROIC) | - | - | -351.47% | - | -147.19% | -90.74% | -95.67% | -121.68% | -120.84% | -105.62% |
Gross Margin | - | - | - | - | 100% | 100% | - | - | - | - |
Net Margin | - | - | - | - | -530.01% | -1062.28% | - | - | - | - |
Debt / Equity | - | 0.01x | 0.09x | 0.04x | 0.01x | 0.13x | 0.21x | 0.18x | 0.12x | 0.06x |
Interest Coverage | - | - | - | - | - | - | - | -365.76x | - | -3198.45x |
FCF Conversion | 0.83x | 0.94x | 0.79x | 0.64x | 1.08x | 1.14x | 0.98x | 0.80x | 0.90x | 0.90x |
Revenue Growth | - | - | - | - | - | -40.57% | -100% | - | - | - |
Related:SLDB Dividend History·SLDB Revenue History·SLDB Price History·SLDB P/E History·SLDB Financial Ratios·SLDB Institutional Holders
SLDB SEC Filings & Documents
Solid Biosciences Inc. (SLDB) SEC filings — annual & quarterly reports (10-K, 10-Q)
SLDB Frequently Asked Questions
Solid Biosciences Inc. (SLDB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Solid Biosciences Inc. (SLDB) grew revenue by 0.0% over the past year. Growth has been modest.
Solid Biosciences Inc. (SLDB) reported a net loss of $191.8M for fiscal year 2025.
Dividend & Returns
Solid Biosciences Inc. (SLDB) has a return on equity (ROE) of -109.9%. Negative ROE indicates the company is unprofitable.
Solid Biosciences Inc. (SLDB) had negative free cash flow of $172.9M in fiscal year 2025, likely due to heavy capital investments.